Literature DB >> 2413079

Primary biliary cirrhosis and chronic active hepatitis: an examination of clinical, biochemical, and histopathological features in differential diagnosis.

J M Williamson, D M Chalmers, A D Clayden, M F Dixon, W S Ruddell, M S Losowsky.   

Abstract

Seventy four liver biopsies from 59 patients were reviewed by two observers and histologically graded in the absence of clinical information, firstly, to assess the level of agreement with previous diagnoses; secondly, to identify differences between primary biliary cirrhosis and chronic active hepatitis; and, thirdly, to assess the specificity of Shikata orcein staining and antimitochondrial antibody positivity and titre for primary biliary cirrhosis. Thirty six patients with adequate histology were initially selected as typical of primary biliary cirrhosis or chronic active hepatitis; agreement both between observers and with original diagnoses was reached in 26 (72%) (15 with primary biliary cirrhosis (group 1), 11 with chronic active hepatitis (group 2)). In 19 diagnostically difficult patients in whom clinical and original histological findings had been at variance, histological agreement between observers was reached in 17 (group 3) and original underdiagnosis of primary biliary cirrhosis was suggested. The main clinical and histological differences between groups 1 and 2 are discussed in this paper. Although a high grade of positivity for copper associated protein in the Shikata orcein stain was seen only in primary biliary cirrhosis, a high titre of antimitochondrial antibody positivity was not unique to this condition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413079      PMCID: PMC499350          DOI: 10.1136/jcp.38.9.1007

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  Posthepatitic cirrhosis clinically simulating extrahepatic biliary obstruction (so-called "primary biliary cirrhosis").

Authors:  W A JONES; W A TISDALE
Journal:  N Engl J Med       Date:  1963-03-21       Impact factor: 91.245

2.  Diagnosis of liver diseases by laboratory results and discriminant analysis. Identification of best combinations of laboratory tests.

Authors:  H E Solberg; S Skrede; J P Blomhoff
Journal:  Scand J Clin Lab Invest       Date:  1975-12       Impact factor: 1.713

3.  [Lupus erythematosus-like syndrome with antimitochondrial antibodies].

Authors:  D Maas; H Schubothe
Journal:  Dtsch Med Wochenschr       Date:  1973-01-26       Impact factor: 0.628

4.  Drug-induced active chronic hepatitis.

Authors:  G B Goldstein; K C Lam; S P Mistilis
Journal:  Am J Dig Dis       Date:  1973-03

5.  Primary biliary cirrhosis and antimitochondrial antibodies.

Authors:  J R Hodges; A J Hall; R Wright
Journal:  Lancet       Date:  1981-08-15       Impact factor: 79.321

6.  Histological demonstration of copper and copper-associated protein in chronic liver diseases.

Authors:  S Jain; P J Scheuer; B Archer; S P Newman; S Sherlock
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

7.  Value of copper-associated protein in diagnostic assessment of liver biopsy.

Authors:  P Guarascio; F Yentis; U Cevikbas; B Portmann; R Williams
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

8.  Demonstration of an intracellular copper-binding protein by orcein staining in long-standing cholestatic liver diseases.

Authors:  M Salaspuro; P Sipponen
Journal:  Gut       Date:  1976-10       Impact factor: 23.059

9.  What does the antimitochondrial antibody mean?

Authors:  D R Triger; C A Charlton; A M Ward
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

10.  Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity.

Authors:  G Klöppel; G Seifert; H Lindner; R Dammermann; H J Sack; P A Berg
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1977-03-11
View more
  9 in total

1.  Presentation of autoantibody to proliferating cell nuclear antigen in patients with chronic hepatitis B and C virus infection.

Authors:  B S Tzang; T Y Chen; T C Hsu; Y C Liu; G J Tsay
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

2.  Plasma membrane association of primary biliary cirrhosis mitochondrial marker antigen M2.

Authors:  U Sundin; K G Sundqvist
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

3.  Osteoporosis and skeletal fractures in chronic liver disease.

Authors:  T Diamond; D Stiel; M Lunzer; M Wilkinson; J Roche; S Posen
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

4.  Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection.

Authors:  Y-Y Wu; T-C Hsu; T-Y Chen; T-C Liu; G-Y Liu; Y-J Lee; G J Tsay
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

5.  Antibody binding and inhibition of pyruvate dehydrogenase (PDH) in sera from patients with primary biliary cirrhosis.

Authors:  U Sundin
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

6.  Specificity of antinuclear antibodies in primary biliary cirrhosis.

Authors:  M J Chou; S L Lee; T Y Chen; G J Tsay
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

7.  Anticentromere antibodies in subjects with no apparent connective tissue disease.

Authors:  S L Lee; G J Tsay; R T Tsai
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

8.  Intraobserver reproducibility in assigning brain tumors to classes in the World Health Organization diagnostic scheme. The Childhood Brain Tumor Consortium.

Authors: 
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

9.  Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report.

Authors:  Asad Javaid; Mugilan Poongkunran; Felicia D Allard; Win Kyaw; Htet Htet Maung; Daryl Lau
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-02-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.